Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials.

BMC Cancer · 2007 · PMC1959236 · PMID 17686164

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

Furthermore, there was a significantly longer overall survival time with 1 year of adjuvant Trastuzumab in the BCIR 006, B-31, N9831 and a clear trend in the other studies.

also in 19,460 other papers

highly significantno p-value reported

In an intent-to treat analysis with a combined median follow-up of two years (2.4 years for B-31 and 1.5 years for N-9831), there was a highly significant 52 percent reduction in the risk of disease recurrence with sequential trastuzumab (three-year DFS 87 versus 75 percent, HR 0.48), and despite the short follow-up, a 33 percent reduction in the risk of death (three-year OS 94.3 versus 91.7 percent, HR 0.67) [ 11 ].

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.